



Updates on EFSA's activities on AMR monitoring

Annual Workshop of the EURL on AMR
Copenhagen, 6-7 April 2014

- Brief overview of the 2014 EUSR on AMR
- Mandate on randomised sampling for AMR monitoring
- ECDC, EFSA and EMA joint analyses of the relationship between antimicrobial consumption and resistance


- ‘Former’ EUCAST Ecoffs used to interpret resistance: *new legislation*
 - AMR commonly found in zoonotic bacteria from humans, animals and food
 - Low levels of **Clinical Resistance** to critically important antimicrobials in humans
 - **Microbiological Resistance** to critically important antimicrobials detected in *Salmonella* and *Campylobacter* in animals and food
 - **Moderate to high** levels for **fluoroquinolones** from broilers and meat
 - **Low** levels for **macrolides** in *Campylobacter* (2011-2012 increases in *C. coli* from broilers)
 - **Low** levels for **3rd generation cephalosporins**
- Consistent increasing (decreasing) trends in resistance to Cip/Nal in *C. jejuni*, *C. coli* and *E. coli* in broilers and pigs in a number of countries
- Low co-resistance levels to CIAs in *Salmonella*, *Campylobacter* and *E. coli*
 - Presentation and Analysis of the multi-drug resistance profiles

- Feedback from Scientific Network meeting on antimicrobial resistance, 27-28 February 2014
- **Mandate on randomised sampling for AMR monitoring**
- ECDC, EFSA and EMA joint analyses of the relationship between antimicrobial consumption and resistance

- Further harmonisation of monitoring and reporting of AMR
 - Active monitoring programmes in healthy animals, based on random sampling plans stratified by age and/or production stage/type, domestically produced
 - e.g. broilers vs. laying hens vs. breeders / fattening veal calves vs. dairy cows
- EC Mandate to EFSA
 - To propose harmonised randomisation procedures for AMR monitoring in samples collected at different stages of the food production chain
 - To provide practical guidance for risk managers in the different Member States for the planning of monitoring programs based on randomised sampling design
 - at slaughterhouse for sampling of carcasses and caeca of broilers, fattening turkeys, slaughter pigs and calves under 1 year of ages
 - at retail, on fresh meat of broilers, pigs and beef

- General approach

- Compromise between ‘good statistical practices’ and practical issues
- Simple and single robust randomised sampling procedure proposed
- (Two-stage) stratified sampling strategy with proportional allocation
- Even distribution over the 4 quarters of the year
- Practical examples of proportional allocations presented in the report



- Exemplary approaches
 - stratified sampling strategy with proportional allocation

	Caeca at slaughter	Meat samples at retail
1 st stage (strata)	Slaughterhouses (60% of national throughput)	NUTS 3 area
Proportional allocation	Sample size proportionate to the SH throughput	Sample size proportionate to the NUTS 3 area population
2 nd stage	Slaughter batches	Retailers
Sample	caecal sample(s) from distinct batches	1 meat sample per retailer
Over-time sample collection	Even sampling every quarter of the year	Even sampling every quarter of the year

Random Sampling of *Salmonella* isolates obtained from *National Control Programmes* in broilers and fattening turkey flocks

- Two possible Approaches are proposed:
 1. *Simple Random Sampling (SRS) in the sampling frame of positive flocks performed every quarter (a (central) database of positive flocks needed)*
 - Isolates transmitted from the official laboratories to AMR laboratory
 - One isolate per positive flock: no clustering issue
 2. *Simple Random Sampling of isolates within the isolate collection of the official laboratories with proportional allocation of the number of isolates*
 - Once isolates have been randomly selected, checking that selected isolates were recovered from differing flocks (epidemiological unit)

Random Sampling of *Salmonella* isolates derived from carcasses of broilers, fattening turkeys, fattening pigs and bovines under 1 year of age in accordance with the relevant points of Chapter 2 of Annex I to Regulation (EC) No 2073/2005

- *Salmonella* isolates should derive from official samples collected by the Competent Authority for verification of compliance with process hygiene criteria and/or,
- In the absence of a sufficient number of isolates, isolates deriving from samples collected by food business operators. *Salmonella* isolates obtained by food business operators are to be provided to the Competent Authority, at its specific request.
- *Simple Random Sampling of isolates within the isolate collection of the official laboratories with proportional allocation of the number of isolates*
 - Once isolates have been randomly selected, checking that selected isolates were recovered from differing plant/epidemiological unit.

- Feedback from Scientific Network meeting on antimicrobial resistance, 27-28 February 2014
- Mandate on randomised sampling for AMR monitoring
- ECDC, EFSA and EMA joint analyses of the relationship between antimicrobial consumption and resistance

- Collaboration between sister agencies of the EU: ECDC, EFSA and EMA
- Common analysis of the relationship between consumption of antimicrobial agents and the occurrence of resistance in humans, animals and food in the EU



- Include data obtained through the surveillance programmes coordinated by EMA, EFSA and ECDC.
- **The respective surveillance networks of the agencies will be informed regularly.**
- The European Union Reference Laboratory for AMR will be informed on the working process.
- The joint report is to be endorsed by EMA, EFSA and ECDC.
- Final version to be delivered to the Commission in 2014.
- The joint report will not substitute the current reports produced by the three agencies.

- This first joint report is the first of a series of reports to be produced at regular intervals.
- Due to the complexity of the tasks and limited resources is not envisaged to produce them yearly, but on a multi-annual basis.
- The early stage of maturity of some of the systems for collecting and analysing data is acknowledged.
- Is foreseen that in the future, as the work of each of the networks progresses towards a more detailed and accurate gathering and analysis of data, a more refined report will be produced.

- The ECDC has provided data on antimicrobial consumption in humans as well as resistance monitoring data on human isolates.
- The EFSA has provided data on monitoring antimicrobial resistance in food and animals
- The EMA has provided data obtained from Member States on antimicrobial consumption in animals (ESVAC data).

- Description of the existing monitoring/surveillance data
- Reporting and limitations of the data
- Complexity of addressing the link between consumption and resistance. Overview of use of antimicrobials in animals and humans
- Which AMs are used – comparison humans vs. animals

- Comparison of sales and resistance in animals
- Comparison of antimicrobial use and resistance in humans
- Identification of critical points for integrated analysis of antimicrobial consumption and resistance obtained from monitoring/surveillance data
- Selected combinations of classes (or subclasses) of antimicrobials and bacteria

- Collaboration of the 3 Agencies on sales and resistance to antimicrobials.
- The report will identify areas for further collaboration and improvement.
- To be published at the end of 2014
- On going project, be patient!

Thank you
for
your attention!